472 Results for GLP-1 Pipeline Update
  • Oncology Insights: 2024 Rewind

    Last year, Oncology Insights brought you the most talked about topics in 2024. As we enter this new year, let us review these impactful and potentially practicing changing subjects that are likely...

  • Prime/MRx experts share clinical insights for migraine treatment

    Drs. Tracey Garcia and Amy Pappas, board-certified neurologists, reviewed migraine risk factors and treatments in a recent webinar moderated by Dr. Marci Chodroff, vice president of medical affairs

    Prime Article: Stories
  • Our history

    Empowering client, providers and members 2024: Using real-time pricing, Pharmacy Match drives affordability for plan sponsors while offering access to the most competitive pharmacy for each member....

  • April Fraud Focus: The latest schemes and FWA trends

    Jessica Johnson, clinical consultant at Prime Therapeutics, shares how the Special Investigations Unit (SIU) helps prevent fraud, waste and abuse (FWA) in health care

    Prime Article: Perspectives
  • Brand Awareness Landing Page

    Whitepaper Tab 1 Myth 1 Myth 2 Myth 3 Myth 4 Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed nec ornare mi. Praesent ultrices ipsum eget est rutrum, eget congue orci molestie. Sed diam...

  • Recapping Prime’s 21st annual Specialty Summit

    Marquee event showcased new Prime, our energy, ambition and transformative journey

    PA Sub-Categories: Specialty drugs Prime Article: Perspectives
  • High-Cost Therapy Profile: June 2024

    Clinical deep dive Disease state overview Myelodysplastic syndromes (MDS) are classified as disorders in which there are abnormal (dysplastic) hematopoietic stem cells in the bone marrow, leading...

  • High Cost Therapy Profile: February 2025

    Clinical deep dive Disease state overview MacTel type 2 is a rare neurodegenerative disease that affects the macula, which processes central and color vision. It is a bilateral asymmetric...